Warner-lambert Company

Eastman-kodak Company

Polygen Holding Corporation

Other

Wayne Livingston Cody

Annette M Doherty

Charles H Foster

John C Hubbs

Cyril Y Bowers

Frank A Momany

John Xiaoqiang He

Michael D Taylor

Patricia DePue

Ching H Chang

Bruce D Roth

David T Connor

Drago R Sliskovic

Michael Francis Rafferty

Helen Tsenwhei Lee

Louis Brogley

Harriet W Hamilton

Annette Marian Doherty

Yuntao Song

Thomas C Malone

Lain-Yen Hu

John G Topliss

Richard John Booth

Randy Ranjee Ramharack

Tomi Sawyer

Laszlo Nadasdi

Robert Lee Panek

Balazs G Szoke

Laszlo Urge

Diego F Silva

Scott R Eaton

Leonard Joseph Lescosky

John X He

Peptidyl calcium channel blockers

Compounds inhibiting the association of the PDGF receptor and

Sulfhydryl containing peptides having the formula

Sulfhydryl containing peptides for treating vascular disease

Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes.

Endothelin antagonists

Methods of using endothelin antagonists

Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders especially cerebral vasospasm, stroke, and head injury, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease, restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, and diabetes.

Endothelin Antagonists II

Disclosed are novel polypeptide compounds which promote the release and elevation of growth hormone levels in the blood of animals. Also disclosed are methods of promoting the release and elevation of growth hormone levels in the blood of animals using the disclosed polypeptide compounds.

Polypeptide compounds having growth hormone releasing activity

Novel polypeptides which promote the release of growth hormone when administered to animals are described. These polypeptides have the formula:

Endotherlin antagonists

Novel linear and monocyclic antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling hypertension, myocardial infarction, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute renal failure, preeclampsia, and diabetes.

Linear and monocyclic endothelin antagonists

Disclosed are combinations of polypeptides acting in a synergistic manner to promote release and elevation of growth hormone levels in the blood of animals. Also disclosed are methods of promoting the release and elevation of growth hormone levels in the blood of animals using the disclosed combination of polypeptides.

Combinations having synergistic growth hormone releasing activity and

Growing community of inventors

Saline, MI, United States of America

Wayne Livingston Cody